Moreover, when anti-CD137 monoclonal antibodies or CD137L injections were tested in cancer therapy, a significant benefit in terms of antitumor response was noticed [21,24,38,48,49,50,51,52,53,54,55,56,57]. The gene discussed is TNFRSF9; the disease is cancer.